RGPX — what changed in the latest 10-Q
A section-by-section comparison of RGPX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2025-11-17 vs the prior 10-Q · 2025-08-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +5 | −3 | ~6 | 21 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~5 | 12 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2025-11-17
On September 22, 2025, the Board of Directors approved changing the company's fiscal year-end from March 31st to December 31st.
Perhaps most exciting is our development of a proprietary AI-driven information system that promises to revolutionize our approach to wound management, patient adherence tracking, and personalized medication protocols. This system, developed in partnership with Optimize Health Partners, will integra…
Results of Operations for the Six Months Ended September 30, 2025 and 2024
At present, the Company has $0 revenue during the six months ended September 30, 2025 and 2024. Net loss increased to $1,477,596 for the six months ended September 30, 2025 from the loss of $802,132 for the six months ended September 30, 2024 due to an increase in research and development, payroll e…
Cash used in investing activities was $38,918 and $0 for the six months ended September 30, 2025 and 2024. This was for information technology systems development.
Text removed vs the prior filing · source: 10-Q · 2025-08-14
Results of Operations for the Three Months Ended June 30, 2024 and 2023
At present, the Company has $0 revenue during the three months ended June 30, 2025 and 2024. Net loss increased from $272,560 for the three months ended June 30, 2024 to $663,584 for the three months ended June 30, 2025 due to an increase in payroll expense and lease costs.
Cash used in investing activities was $0 and $0 for the three months ended June 30, 2025 and 2024.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice